NCT01105429

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-820132 in Subjects With Type 2 Diabetes on Background Therapy of Metformin

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug, as well as the amount of study drug in the blood, in subjects with type 2 diabetes.

Conditions

• Diabetes Mellitus, Non-Insulin-Dependent

Interventions

Type	Name	Description
DRUG	BMS-820132	Oral Solution, Oral, 0.3 mg, once daily, 1 day
DRUG	BMS-820132	Oral Solution, Oral, 1.0 mg, once daily, 1 day
DRUG	BMS-820132	Oral Solution, Oral, 3 mg, once daily, 1 day
DRUG	BMS-820132	Oral Solution, Oral, 10 mg, once daily, 1 day
DRUG	BMS-820132	Oral Solution, Oral, 30 mg, once daily, 1 day
DRUG	BMS-820132	Oral Solution, Oral , 75 mg, once daily, 1 day
DRUG	BMS-820132	Oral Solution, Oral, 150 mg, once daily, 1 day
DRUG	BMS-820132	Oral Solution, Oral, 300 mg, once daily, 1 day
DRUG	BMS-820132	Capsule, Oral, (TBD), once daily, 2 days
DRUG	Placebo	Oral Solution, Oral, 0mg, once daily, 1 day
DRUG	Placebo	Capsule, Oral, (TBD), once daily, 2 days

Timeline

• Start date: 2010-05-01
• Primary completion: 2010-10-01
• Completion: 2010-10-01
• First posted: 2010-04-16
• Last updated: 2011-03-09

Locations

3 sites across 1 country: United States